pfkb-1.2 Antibody

What is pfkb-1.2 and why is it important in C. elegans research?

pfkb-1.2 encodes a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK/FBPase) enzyme that plays crucial roles in carbohydrate metabolism in C. elegans. This bifunctional enzyme (EC 3.1.3.46; EC 2.7.1.105) comprises 457 amino acids and is involved in regulating glycolysis and gluconeogenesis through the synthesis and degradation of fructose-2,6-bisphosphate. The protein is categorized as "Hard" in the AbClass™ classification system, indicating potential challenges in antibody development. Research on this protein helps elucidate metabolic regulation in nematodes and provides comparative insights into evolutionary conservation of metabolic pathways across species .

What types of pfkb-1.2 antibodies are commercially available for C. elegans research?

Commercial pfkb-1.2 antibodies typically consist of combinations of monoclonal antibodies targeting different regions of the protein. The available formulations include:

These antibody combinations can be further deconvoluted into individual monoclonal antibodies after epitope determination if needed for more specific applications .

How should I validate pfkb-1.2 antibody specificity before experimental use?

Antibody validation is critical for ensuring experimental reliability. For pfkb-1.2 antibodies, follow these methodological approaches:

• Western blot analysis: Run protein extracts from wild-type C. elegans alongside extracts from pfkb-1.2 knockout or knockdown worms. The antibody should detect a band at approximately 50 kDa in wild-type samples but show reduced or absent signal in mutants.

• Immunoprecipitation validation: Perform IP followed by mass spectrometry to confirm that pulled-down proteins include pfkb-1.2 and expected interaction partners.

• Cross-reactivity assessment: Test against recombinant pfkb-1.2 protein alongside related family members to verify specificity.

• Epitope mapping: Consider epitope determination services to identify the exact binding sites of individual monoclonal antibodies within the combination, especially important for distinguishing between closely related proteins .

This comprehensive validation approach aligns with principles used in antibody development for other complex proteins, where identification of distinct binding modes can help predict and improve specificity .

What are the optimal sample preparation techniques for pfkb-1.2 detection in C. elegans?

For optimal pfkb-1.2 detection in C. elegans samples, the following sample preparation methodology is recommended:

• Protein extraction:

  • Use synchronized worm populations to minimize developmental variability

  • Harvest worms by washing with M9 buffer and flash-freeze in liquid nitrogen

  • Homogenize frozen worm pellets using a bead beater in lysis buffer containing protease inhibitors

  • Include phosphatase inhibitors if studying the phosphorylation state of pfkb-1.2

• Sample handling:

  • Process samples at 4°C to prevent protein degradation

  • Avoid repeated freeze-thaw cycles

  • For membrane-associated fractions, consider using detergent-based extraction methods

  • Quantify protein concentration using Bradford or BCA assay for consistent loading

• Sample fractionation:

  • Consider subcellular fractionation to enrich for cytosolic components where pfkb-1.2 is predominantly found

  • For developmental studies, prepare separate extracts from different larval stages and adults

This approach ensures maximum preservation of native protein conformation and facilitates accurate detection of the target protein in complex biological samples.

How can I distinguish between different isoforms of pfkb-1.2 using the available antibodies?

Distinguishing between pfkb-1.2 isoforms requires strategic use of the available antibody combinations and advanced experimental techniques:

• Strategic antibody selection:

  • Use region-specific antibody combinations (N, M, or C-terminal) to identify potential isoforms that may be truncated or alternatively spliced

  • Consider using multiple combinations simultaneously in parallel experiments for comprehensive coverage

  • Analyze migration patterns on high-resolution gels to detect subtle size differences

• Complementary techniques:

  • Combine antibody detection with RNA-seq data to correlate protein detection with transcript expression

  • Employ 2D gel electrophoresis to separate proteins based on both size and charge

  • Use phospho-specific staining to identify differentially phosphorylated isoforms

• Advanced validation:

  • Express recombinant versions of predicted isoforms as positive controls

  • Consider generating isoform-specific antibodies if the existing combinations cannot adequately differentiate between closely related variants

  • Use CRISPR/Cas9 to tag endogenous isoforms for tracking expression and localization

These approaches enable researchers to map specific antibody binding to different structural elements of pfkb-1.2, similar to biophysics-informed models used to disentangle binding modes for other complex proteins .

What controls should be included when studying temporal expression patterns of pfkb-1.2 during C. elegans development?

When studying temporal expression patterns of pfkb-1.2 during C. elegans development, a robust system of controls is essential:

• Essential controls:

  • Genetic controls: Include pfkb-1.2 null mutants as negative controls

  • Loading controls: Use antibodies against invariant proteins like actin or tubulin to normalize expression levels

  • Developmental stage markers: Include antibodies against stage-specific proteins to confirm accurate staging

  • Cross-reactivity controls: Test antibodies against recombinant pfkb-1.2 and closely related family members

• Temporal sampling strategy:

  • Collect synchronized populations at defined time points (embryonic, L1-L4, young adult, aged adult)

  • Use temperature-sensitive mutants to synchronize populations with greater precision

  • Consider using alternative synchronization methods for different developmental questions

• Data normalization approach:

  • Normalize pfkb-1.2 expression to total protein content

  • Consider normalization to cell number or biomass for developing tissues

  • Track multiple reference genes/proteins to ensure robust normalization across developmental stages

This systematic approach with appropriate controls enables reliable tracking of pfkb-1.2 expression dynamics throughout development, minimizing experimental artifacts and allowing for accurate comparisons between different developmental stages.

What are common pitfalls when using pfkb-1.2 antibodies in immunoprecipitation experiments?

Researchers frequently encounter specific challenges when using pfkb-1.2 antibodies for immunoprecipitation in C. elegans samples. Here are methodological solutions to common pitfalls:

• Poor antibody binding efficiency:

  • Pre-clear lysates thoroughly to remove non-specific binding proteins

  • Optimize antibody concentration - typical starting dilution is 1:50 for immunoprecipitation

  • Consider cross-linking antibodies to beads to prevent antibody contamination in eluted samples

  • Test different antibody combinations (N-terminal, C-terminal, middle region) to identify optimal binding configurations

• Co-immunoprecipitation challenges:

  • Adjust lysis buffer conditions to preserve protein-protein interactions

  • Use gentle detergents like NP-40 or Triton X-100 at 0.1-0.5%

  • Add protease inhibitors fresh before each experiment

  • Consider formaldehyde cross-linking to capture transient interactions

• Background and specificity issues:

  • Include IgG control immunoprecipitations

  • Perform reciprocal IPs with antibodies against known interaction partners

  • Validate IP specificity using western blot before proceeding to downstream applications

  • Consider using more stringent washing conditions to reduce non-specific binding

The principles used in antibody-antigen interaction optimization for immunoprecipitation follow similar biophysical considerations as those used in computational models for antibody specificity design .

How should I interpret contradictory results between different pfkb-1.2 antibody combinations?

When facing contradictory results between different pfkb-1.2 antibody combinations, apply this systematic analysis methodology:

• Technical validation:

  • Verify each antibody's specificity using western blot against recombinant protein

  • Check for potential interference from post-translational modifications masking epitopes

  • Evaluate whether different fixation or sample preparation methods affect epitope accessibility

  • Assess whether the contradictions appear in all experimental systems or are context-dependent

• Biological interpretation:

  • Consider that different antibody combinations target distinct regions (N, M, C-terminal), and contradictory results may reveal:

    • Protein processing or cleavage events

    • Alternative splicing generating isoforms lacking specific domains

    • Differential protein complex formation masking epitopes

    • Developmental or condition-specific conformational changes

• Resolution approach:

  • Employ complementary non-antibody techniques (e.g., mass spectrometry, RNA-seq)

  • Use genetic tagging (GFP, FLAG) to validate expression patterns

  • Perform domain-specific functional tests to correlate with antibody detection patterns

  • Consider epitope mapping to precisely identify binding sites for each antibody in the combinations

This analytical framework transforms contradictory results into opportunities for deeper biological insight about pfkb-1.2 structure, processing, and regulation in C. elegans.

How can pfkb-1.2 antibodies be used to study metabolic regulation in C. elegans disease models?

pfkb-1.2 antibodies provide valuable tools for investigating metabolic dysregulation in C. elegans disease models, with applications in several research areas:

• Neurodegenerative disease models:

  • Track pfkb-1.2 expression and localization changes in Alzheimer's, Parkinson's, or Huntington's disease models

  • Correlate metabolic enzyme changes with disease progression

  • Study the relationship between glucose metabolism alterations and protein aggregation

  • Investigate potential protective effects of metabolic interventions

• Metabolic syndrome and diabetes models:

  • Analyze pfkb-1.2 expression in insulin signaling pathway mutants

  • Study the relationship between altered carbohydrate metabolism and lipid accumulation

  • Investigate how dietary interventions affect pfkb-1.2 levels and activity

  • Examine the metabolic response to stress conditions in wild-type versus disease models

• Aging studies:

  • Track pfkb-1.2 expression changes throughout lifespan

  • Correlate metabolic enzyme alterations with aging phenotypes

  • Investigate how interventions that extend lifespan affect pfkb-1.2 expression

  • Study the relationship between mitochondrial function and glycolytic regulation

These applications combine antibody-based detection methods with genetic manipulation and physiological measurements to provide comprehensive insights into how metabolic enzyme function contributes to disease processes.

What emerging technologies might enhance the specificity and application range of pfkb-1.2 antibodies?

Emerging technologies offer promising avenues to enhance pfkb-1.2 antibody applications in C. elegans research:

• Computational antibody engineering:

  • Biophysics-informed models can identify and disentangle multiple binding modes for improved specificity

  • Machine learning approaches can predict cross-reactivity and optimize antibody sequences

  • Computational design can generate antibodies with customized specificity profiles targeting distinct epitopes or isoforms

  • These approaches enable the creation of antibodies not present in initial libraries with precisely defined binding characteristics

• Advanced microscopy integration:

  • Super-resolution microscopy combined with highly specific antibodies enables precise subcellular localization

  • Single-molecule detection techniques can reveal dynamics of low-abundance proteins

  • Correlative light and electron microscopy using antibody labeling provides contextualized ultrastructural information

  • Expansion microscopy with antibody detection offers enhanced spatial resolution in intact tissues

• Multiplexed detection systems:

  • Mass cytometry with metal-conjugated antibodies allows simultaneous detection of numerous targets

  • Sequential epitope detection methods permit highly multiplexed imaging in fixed samples

  • Barcoded antibody techniques enable high-throughput analysis across multiple conditions

  • Combined antibody-based detection with CRISPR-based labeling provides complementary localization data

These technological advances represent the frontier of antibody-based research tools that will drive new discoveries in C. elegans metabolism and disease modeling.

What are the optimal fixation and permeabilization conditions for immunofluorescence detection of pfkb-1.2 in C. elegans tissues?

Optimizing fixation and permeabilization for pfkb-1.2 immunofluorescence in C. elegans requires careful consideration of multiple parameters:

• Fixation protocols for different applications:

  • Standard formaldehyde fixation: 4% paraformaldehyde in PBS for 30 minutes at room temperature preserves most epitopes while maintaining tissue morphology

  • Methanol fixation: 100% methanol at -20°C for 5 minutes may improve detection of certain epitopes by exposing internal protein domains

  • Hybrid protocol: Sequential fixation with paraformaldehyde followed by methanol treatment combines benefits of both approaches

  • Glutaraldehyde addition: For microscopic ultrastructure preservation, include 0.1-0.5% glutaraldehyde, but test for epitope masking

• Permeabilization optimization:

  • Triton X-100: 0.1-0.5% in PBS for 10-30 minutes for general permeabilization

  • Freeze-cracking: Rapid freezing and thawing to create microscopic ice crystal disruptions for improved antibody access

  • Collagenase treatment: Brief enzymatic digestion (0.1-1 mg/ml) to break down cuticle barriers

  • β-mercaptoethanol/DTT: Reduction of disulfide bonds in cuticle can enhance penetration

• Tissue-specific considerations:

  • Neurons: Longer permeabilization times may be needed for dense neural tissues

  • Intestine: Autofluorescence quenching steps with sodium borohydride may improve signal-to-noise ratio

  • Germline: Special attention to preservation of subcellular structures while maintaining antibody accessibility

Each of these conditions should be systematically tested with the available pfkb-1.2 antibody combinations to determine optimal protocols for specific experimental applications.

How can quantitative western blot analysis be optimized for measuring subtle changes in pfkb-1.2 expression levels?

For detecting subtle changes in pfkb-1.2 expression levels, quantitative western blot analysis can be optimized using the following methodological approach:

• Sample preparation refinements:

  • Standardize protein extraction using mechanical homogenization with precise buffer-to-sample ratios

  • Prepare samples at 4°C with freshly added protease/phosphatase inhibitors

  • Quantify protein concentration using bicinchoninic acid (BCA) assay with standard curves

  • Prepare single-use aliquots to avoid freeze-thaw degradation

• Technical optimization:

  • Use gradient gels (4-15%) for optimal protein separation

  • Perform wet transfers at constant amperage (recommended: 1:1000 antibody dilution for western blotting)

  • Include concentration gradients of recombinant pfkb-1.2 protein for absolute quantification

  • Employ fluorescent secondary antibodies rather than chemiluminescence for wider linear dynamic range

• Controls and normalization:

  • Run biological triplicates and technical duplicates

  • Include multiple housekeeping proteins as loading controls (actin, tubulin, GAPDH)

  • Use total protein staining (SYPRO Ruby, Ponceau S) as an alternative normalization method

  • Consider normalizing to multiple reference proteins rather than a single housekeeping gene

• Data analysis:

  • Use image analysis software with background subtraction

  • Generate standard curves to ensure measurements within linear detection range

  • Apply appropriate statistical tests for small sample comparisons

  • Consider transformations for non-normally distributed data

This comprehensive approach enables detection of expression changes as small as 10-15%, essential for studying subtle regulatory effects on metabolic enzymes like pfkb-1.2.

How can temporal antibody dynamics be studied to understand the relationship between pfkb-1.2 and developmental metabolic shifts in C. elegans?

Studying temporal antibody dynamics to understand pfkb-1.2's role in developmental metabolic shifts requires a multi-faceted methodological approach:

• Developmental time course analysis:

  • Establish precisely synchronized populations using staged egg lay techniques

  • Collect samples at defined intervals throughout development (early embryo, late embryo, L1-L4, young adult)

  • Process all samples simultaneously to minimize batch effects

  • Consider both whole-animal lysates and tissue-specific extracts using sorting techniques

• Multi-parameter analysis:

  • Correlate pfkb-1.2 protein levels with enzymatic activity measurements

  • Simultaneously track metabolite levels using mass spectrometry

  • Monitor energy status indicators (ATP/ADP ratio, AMPK activation)

  • Relate protein expression to transcriptional dynamics using parallel RNA analysis

• Perturbation approaches:

  • Employ temperature-shift experiments with conditional alleles to trigger rapid changes

  • Use optogenetic or chemical tools for acute metabolic pathway manipulation

  • Apply dietary interventions at specific developmental stages

  • Analyze recovery dynamics after transient metabolic stress

This approach draws inspiration from longitudinal antibody studies in other systems, such as the dynamics of PfEMP1 antibodies from birth to 12 months, which demonstrated how antibody profiles change over developmentally significant timeframes .

What are the considerations for developing phospho-specific antibodies to study pfkb-1.2 regulation in C. elegans?

Developing phospho-specific antibodies for pfkb-1.2 requires careful consideration of several technical and biological factors:

• Phosphorylation site identification and selection:

  • Conduct phosphoproteomic analysis to identify endogenous phosphorylation sites

  • Prioritize evolutionarily conserved sites with predicted functional significance

  • Select sites with favorable surrounding sequences for antibody generation

  • Consider targeting both regulatory and non-regulatory sites as controls

• Antibody development strategy:

  • Generate phosphopeptides with precise modifications at target residues

  • Consider dual approach of phospho-specific and corresponding non-phospho antibodies

  • Employ double purification: positive selection for phospho-epitope and negative selection against non-phospho version

  • Validate with phosphatase treatment and site-directed mutagenesis

• Validation requirements:

  • Test against recombinant proteins with defined phosphorylation states

  • Verify specificity using phosphatase treatments and phosphomimetic mutations

  • Confirm detection under physiological conditions where phosphorylation is regulated

  • Demonstrate correlation between antibody signal and mass spectrometry-verified phosphorylation

• Application considerations:

  • Optimize sample preparation to preserve phosphorylation status

  • Include phosphatase inhibitors in all buffers

  • Consider rapid sample processing to capture transient phosphorylation events

  • Develop protocols for enrichment of phosphorylated species before detection

These methodological considerations align with advanced approaches for designing antibodies with customized specificity profiles, ensuring precise detection of defined post-translational modifications .

How can C. elegans pfkb-1.2 antibodies contribute to understanding evolutionarily conserved metabolic pathways across species?

C. elegans pfkb-1.2 antibodies can serve as valuable tools for comparative studies of metabolic regulation across species, with several methodological applications:

• Cross-reactivity assessment and application:

  • Test C. elegans pfkb-1.2 antibodies against orthologous proteins from related nematodes

  • Evaluate potential cross-reactivity with mammalian PFKFB isoforms (particularly PFKFB3)

  • Map epitope conservation across species using sequence alignment and structural modeling

  • Develop strategies for using the same antibodies across multiple model organisms where epitopes are conserved

• Comparative metabolic studies:

  • Use antibodies to compare expression patterns and subcellular localization across species

  • Analyze differential post-translational modifications of conserved metabolic enzymes

  • Investigate species-specific regulatory mechanisms affecting the same core metabolic pathways

  • Examine how environmental responses affect orthologous proteins across evolutionary distance

• Translational research applications:

  • Apply insights from C. elegans pfkb-1.2 studies to mammalian metabolism

  • Investigate conserved disease-related metabolic dysregulation across model systems

  • Use antibody detection to validate cross-species genetic rescue experiments

  • Develop screening platforms using C. elegans to identify compounds affecting conserved targets

This comparative approach contributes to our understanding of fundamental metabolic regulation while leveraging the experimental advantages of the C. elegans model system.

What methodological adaptations are needed when using pfkb-1.2 antibodies for multi-omics integration studies?

Integrating pfkb-1.2 antibody data with other omics approaches requires specific methodological considerations:

• Sample preparation harmonization:

  • Develop protocols allowing simultaneous extraction of proteins, RNA, and metabolites from the same samples

  • Standardize collection timepoints and conditions across all omics platforms

  • Consider splitting samples for specialized extractions while maintaining biological coherence

  • Implement careful sample tracking and metadata documentation for integration

• Data normalization and integration challenges:

  • Establish common reference standards across platforms

  • Develop computational pipelines for correlating antibody-based protein quantification with transcriptomics and metabolomics

  • Account for different dynamic ranges and temporal relationships between molecular species

  • Address the challenge of different detection sensitivities across platforms

• Validation strategies:

  • Perform targeted validation experiments testing predictions from integrated analyses

  • Use orthogonal techniques to confirm key findings

  • Implement causal perturbation experiments to test relationships identified through correlation

  • Develop visualization methods that effectively communicate multi-omics relationships

• Analytical frameworks:

  • Apply machine learning approaches to identify patterns across multi-omics datasets

  • Utilize pathway and network analyses to place pfkb-1.2 in broader biological context

  • Develop kinetic models incorporating protein levels, activity measurements, and metabolite fluxes

  • Consider Bayesian frameworks to integrate prior knowledge with experimental data